Intravitreal bevacizumab and ranibizumab for age-related macular degeneration a multicenter, retrospective study

scientific article

Intravitreal bevacizumab and ranibizumab for age-related macular degeneration a multicenter, retrospective study is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.OPHTHA.2009.07.023
P698PubMed publication ID19969368

P2093author name stringDonald S Fong
Jin-Wen Hsu
Jennifer Howes
Peter Custis
P433issue2
P921main subjectmacular degenerationQ27429789
bevacizumabQ413299
multicenter clinical trialQ6934595
P304page(s)298-302
P577publication date2009-12-06
P1433published inOphthalmologyQ7098109
P1476titleIntravitreal bevacizumab and ranibizumab for age-related macular degeneration a multicenter, retrospective study
P478volume117

Reverse relations

cites work (P2860)
Q84251275A prospective study on different methods for the treatment of choroidal neovascularization. The efficacy of verteporfin photodynamic therapy, intravitreal bevacizumab and transpupillary thermotherapy in patients with neovascular age-related macular
Q92523288A systematic approach to evaluate practice-based process- and outcome data applied to the treatment of neovascular age-related macular degeneration
Q37361023Anti-VEGF-refractory exudative age-related macular degeneration: differential response according to features on optical coherence tomography.
Q92480382Assessment of bevacizumab quality and stability in repackaged syringes for clinical use
Q49176127Association of genetic polymorphisms with response to bevacizumab for neovascular age-related macular degeneration in the Chinese population
Q82063645Bevacizumab and Ocular Wound Healing After Primary Pterygium Excision
Q35705156Bevacizumab in clinical practice: prescribing appropriateness relative to national indications and safety
Q37996922Bevacizumab nasal spray: Noninvasive treatment of epistaxis in patients with Rendu-Osler disease
Q41915161Bevacizumab versus Ranibizumab on As-Needed Treatment Regimen for Neovascular Age-Related Macular Degeneration in Turkish Patients
Q34139793Clinical utilization of anti-vascular endothelial growth-factor agents and patient monitoring in retinal vein occlusion and diabetic macular edema
Q35060360Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration
Q35162123Comparison of bevacizumab and ranibizumab in age-related macular degeneration: a systematic review and meta-analysis
Q35923834Comparison of visual acuity outcomes between ranibizumab and bevacizumab treatment in neovascular age-related macular degeneration
Q36907322Delay to treatment and visual outcomes in patients treated with anti-vascular endothelial growth factor for age-related macular degeneration
Q38867052Economic Evaluation of a Home-Based Age-Related Macular Degeneration Monitoring System
Q42324331Exogenous group G Streptococcus endophthalmitis following intravitreal ranibizumab injection
Q42734263Feasibility and efficacy of a mass switch from ranibizumab (Lucentis) to bevacizumab (Avastin) for treatment of neovascular age-related macular degeneration
Q36596476Incidence of Endophthalmitis after Intravitreal Anti-vascular Endothelial Growth Factor: Experience in Saudi Arabia
Q36596479Incidence of Endophthalmitis after Intravitreal Bevacizumab using Aliquots Prepared On-site in 2 Operating Rooms in Kuwait
Q37792817Inflammatory mediators and angiogenic factors in choroidal neovascularization: pathogenetic interactions and therapeutic implications
Q38764072Intravitreal Bevacizumab and Cardiovascular Risk in Patients with Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Randomized Controlled Trials and Observational Studies
Q35641933Lasting controversy on ranibizumab and bevacizumab
Q88391709Letter to the Editor
Q35560661Medicare costs for neovascular age-related macular degeneration, 1994-2007.
Q35127099Ocular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degeneration
Q38477676Photodynamic therapy combined with intravitreal injection of vascular endothelial growth factor antibody for polypoidal choroidal vasculopathy
Q42770014Predictors of response after intravitreal bevacizumab injection for neovascular age-related macular degeneration.
Q37570185Randomized trial of a home monitoring system for early detection of choroidal neovascularization home monitoring of the Eye (HOME) study
Q37801665Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration
Q37550855Switching from intravitreal ranibizumab to bevacizumab for age-related macular degeneration
Q38210239Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration: an overview.
Q26849299The therapeutic potential of intraocular depot steroid systems: developments aimed at prolonging duration of efficacy
Q39321127Therapeutic targeting of the angiopoietin-TIE pathway
Q36770126Transforming care delivery through health information technology

Search more.